Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Biomedical Engineering
SJR: 0.207 SNIP: 0.376 CiteScore™: 0.79

ISSN Print: 0278-940X
ISSN Online: 1943-619X

Critical Reviews™ in Biomedical Engineering

DOI: 10.1615/CritRevBiomedEng.v38.i2.30
pages 143-156

Molecular Networks in Drug Discovery

John Kenneth Morrow
The Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Longzhang Tian
The Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Shuxing Zhang
The Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

ABSTRACT

Despite the dramatic increase of global spending on drug discovery and development, the approval rate for new drugs is declining, due chiefly to toxicity and undesirable side effects. Simultaneously, the growth of available biomedical data in the postgenomic era has provided fresh insight into the nature of redundant and compensatory drug-target pathways. This stagnation in drug approval can be overcome by the novel concept of polypharmacology, which is built on the fundamental concept that drugs modulate multiple targets. Polypharmacology can be studied with molecular networks that integrate multidisciplinary concepts including cheminformatics, bioinformatics, and systems biology. In silico techniques such as structure- and ligand-based approaches can be employed to study molecular networks and reduce costs by predicting adverse drug reactions and toxicity in the early stage of drug development. By amalgamating strides in this informatics-driven era, designing polypharmacological drugs with molecular network technology exemplifies the next generation of therapeutics with less of-target properties and toxicity. In this review, we will first describe the challenges in drug discovery, and showcase successes using multitarget drugs toward diseases such as cancer and mood disorders. We will then focus on recent development of in silico polypharmacology predictions. Finally, our technologies in molecular network analysis will be presented.


Articles with similar content:

Current Vaccination Strategies for the Treatment of B-Cell Lymphoma and Multiple Myeloma
Critical Reviews™ in Immunology, Vol.29, 2009, issue 5
Nurit Hollander
Self-Emulsifying Drug Delivery Systems (SEDDS): Formulation Development, Characterization, and Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.26, 2009, issue 5
Shantanu Bandopadhyay, Ramandeep Singh, Bhupinder Singh, Rishi Kapil, Om Parkash Katare
Regulatory T-Cell Therapy in Transplantation and Severe Autoimmunity
Critical Reviews™ in Immunology, Vol.35, 2015, issue 6
Roberto Spreafico, Maura Rossetti
Phosphorylation Signaling in Mycobacterium Tuberculosis: An Overview
Forum on Immunopathological Diseases and Therapeutics, Vol.6, 2015, issue 3-4
Angela C. O. Menegatti, Hernan Terenzi
Immunocytokines for Cancer Therapy
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 1-2
Dario Neri, Philipp Probst